Multimodality Cardiovascular Molecular Imaging, Part II

Matthias Nahrendorf, MD, PhD; David E. Sosnovik, MD; Brent A. French, PhD; Filip K. Swirski, PhD; Frank Bengel, MD; Mehran M. Sadeghi, MD; Jonathan R. Lindner, MD; Joseph C. Wu, MD, PhD; Dana L. Kraitman, VMD, PhD; Zahi A. Fayad, PhD; Albert J. Sinusas, MD

Molecular imaging has the potential to profoundly impact preclinical research and future clinical cardiovascular care. In Part I of this 2-part consensus article on multimodality cardiovascular molecular imaging, the imaging methodology, evolving imaging technology, and development of novel targeted molecular probes relevant to the developing field of cardiovascular molecular imaging were reviewed. Part II of this consensus article will review the targeted imaging probes available for the identification and evaluation of critical pathophysiological processes in the cardiovascular system. These include novel imaging strategies for the evaluation of inflammation, thrombosis, apoptosis, necrosis, vascular remodeling, and angiogenesis. The current article will also review the role of targeted imaging of a number of cardiovascular diseases, including atherosclerosis, ischemic injury, postinfarction remodeling, and heart failure, as well as the emerging fields of regenerative, genetic, and cell-based therapies. Special emphasis is placed on multimodal imaging, as these hybrid techniques promise to advance the field by combining approaches with complementary strengths and offsetting limitations.

Although some applications of molecular imaging are well established, other clinical applications are under development and still emerging, such as early detection of atherosclerosis or unstable plaque. The goals of molecular imaging are to refine risk assessment, facilitate the early diagnosis of disease before the occurrence of debilitating events, aid in the development of personalized therapeutic regimens and to monitor the efficacy of complex therapies. However, to translate the evolving targeted imaging probes, technologies, and applications into clinical care, the imaging community will need to overcome several hurdles. Therefore, the current review will also discuss the opportunities and challenges associated with the implementation and advancement of targeted molecular imaging in clinical practice, and the realization of image-directed personalized medicine.

Critical Pathophysiological Processes

In this initial section, we will review the role of targeted molecular imaging for the evaluation of a number of critical pathophysiological processes of the cardiovascular system.

Inflammation

The chemical and spatiotemporal diversity of inflammatory factors and a growing appreciation of inflammation in cardiovascular disease have engendered interest in targeting the immune system for cardiovascular molecular imaging. Among the prospective targets, proteolytic enzymes and circulating leukocytes have received the most attention. The development of "smart" protease-activatable probes equipped with specific peptide sequences that can be recognized by proteases (ie, cathepsins, matrix metalloproteinases [MMPs]) and that, on enzyme recognition and cleavage, dequench their fluorochromes and fluoresce, has given rise to optical imaging of proteolysis in a number of cardiovascular conditions.

Studies investigating the accumulation of leukocytes to tissue reflect directly how inflammation can be targeted for molecular imaging of the inflammatory cascade. A number of ex vivo and in vivo approaches in both atherosclerosis and heart failure have reported sensitive and quantitative imaging of monocyte accumulation to inflammatory sites (Figure 1). Naturally phagocytic, these myeloid cells can be labeled easily with optical, nuclear, and superparamagnetic...
agents for multiscopic, multimodality imaging. Cell trackers such as VT680, a near-infrared reagent that allows for in vivo multiscopic imaging, readily labels leukocytes ex vivo. In-oxine, an FDA-approved isotope cell-tracker can report on monocyte accumulation in atherosclerosis and heart failure by autoradiography and single-photon emission computed tomography (SPECT)/computed tomography (CT) imaging. For studies in which longer tracking times are needed, stably-transfected fluorescent proteins under control of specific promoters can be used. For example, mice that express green fluorescent protein under the CX3CR1 promoter have yielded valuable insights into monocyte biology. Collectively, these studies have begun to illuminate the kinetics of cellular infiltration in living animals and thus have provided novel biological insight as well as the possibility for clinical translation. Among the challenges that remain are the high cell turnover rates that dilute signal and prevent long-term imaging, possible activation and cell loss due to ex vivo labeling, the need to discriminate between various myeloid subsets, and the need to target selectively nonphagocytic leukocytes. As more mechanistic insights of immune mechanisms that govern cardiovascular disease become available through classical and imaging approaches, imaging targets will be identified with the hope to, eventually, image the inflammatory cascade comprehensively at its various stages.

**Thrombosis**

Thrombosis plays a central role in myocardial infarction, stroke, atrial fibrillation and venous thrombo-embolism. The potential of molecular imaging in these conditions is 2-fold: (1) to physically detect and diagnose thrombi and (2) to characterize their nature and propensity to respond to anticoagulation and thrombolysis. Strategies to image the central events in thrombus formation including platelet activation, the generation of fibrin, and the cross-linking of fibrin strands by FXIII, have been developed. Ligands to the glycoprotein IIbIIIa receptor have been conjugated to technetium, and iron-oxide microparticles for SPECT and MRI, respectively. A peptide specific for activated FXIII has been used to image venous thrombosis using fluorescence imaging techniques in vivo. However, the most extensive experience to date in the imaging of thrombosis in vivo has been with EP2104R (Epix Pharmaceuticals, Lexington, Mass) a small gadolinium chelate targeted to fibrin. Studies with EP2104R in rabbits and swine documented the ability of the agent to detect acute and chronic arterial and venous thrombi. On the basis of this extensive preclinical experience, 52 patients with suspected thrombosis have now been imaged with this agent. The initial clinical experience with EP2104R shows that the agent is able to successfully detect arterial, venous and intracardiac thrombosis in humans (Figure 2). This important experience demonstrates both the feasibility and potential value of targeted cardiovascular molecular MRI in patients.

**Apoptosis**

Apoptosis plays an important role in diseases of both the myocardium and the vasculature. During ischemia-reperfusion up to 30% of cardiomyocytes (CMs) in the injured myocardium become apoptotic. The level of CM apoptosis in heart failure is significantly lower (<1%) but persists over many months resulting in the net loss of a large number of CMs. The inhibition of apoptosis with caspase-
rejection. Coronary syndromes, heart failure, and transplant in the myocardium can be imaged with this agent in the acute phase. A strong correlation was seen in this study between uptake of the 99mTc annexin-V in a patient before carotid endarterectomy. A similar correlation has been observed in other studies.

Figure 3. Apoptosis. A–C, Molecular MRI of CM apoptosis in vivo in a mouse model of ischemia-reperfusion, adapted with permission.33 A, The apoptosis sensing magnetofluorescent nanoparticle, AnxCLIO-Cy5.5, accumulates in injured myocardium producing signal hypointensity (arrow) and a reduction in T2*. B and C, In vivo T2* maps created in regions of myocardium with equivalent degrees of hypokinesis in a mouse injected with AnxCLIO-Cy5.5 (B) and a mouse injected with the control probe (C). D and E, Imaging of cell death with technetium-labeled annexin in a patient with an acute coronary syndrome, adapted with permission.36 D, Perfusion defect (arrow) in the patient 6 to 8 weeks after the acute coronary syndrome. E, Uptake of 99mTc annexin-V (arrow) at the time of the event correlates well with the perfusion defect. L, liver. F, Uptake of 99mTc annexin-V in a patient before carotid endarterectomy. A strong correlation was seen in this study between uptake of the probe and macrophage content of the plaque, adapted with permission.36

Inhibitors in animal models of both ischemia-reperfusion and heart failure is highly cardioprotective.24–26 Modulation of CM apoptosis thus provides an attractive target for both molecular imaging and therapy of cardiovascular disease.

The hallmark of apoptosis is the activation of the cytoplasmic protease caspase-3. Small molecules, such as isatins, have been labeled with positron-emission tomography (PET) tracers and used to target caspase-3, but the experience with these agents in still very preliminary. A more extensively used approach has been to target the presence of phosphatidylserine on the outer cell membrane of apoptotic cells.28 Phosphatidylserine is a membrane phospholipid, normally found only on the inner cell membrane, which becomes translocated to the outer cell membrane soon after the activation of caspase-3. Phosphatidylserine on the apoptotic cell membrane has been targeted with Annexin V25 and the C2 domain of synaptotagmin.29 Pioneering work with technetium-labeled annexin in humans has shown that cell death in the myocardium can be imaged with this agent in the acute coronary syndromes, heart failure, and transplant rejection.32

More recently, approaches to image CM apoptosis with molecular MRI have been developed.33 Annexin V was conjugated to the magnetofluorescent nanoparticle, CLIO-Cy5.5, to yield the magnetofluorescent annexin, AnxCLIO-Cy5.5. This construct has a level of biological activity similar to that of unmodified annexin, and has been shown to colocalize strongly with Annexin-fluorescein isothiocyanate.33,34 AnxCLIO-Cy5.5 has been used to image CM apoptosis by MRI in vivo in a mouse model of ischemia reperfusion (Figure 3).33 Annexin has also been conjugated to a small gadolinium loaded liposome and used to image CM apoptosis in an isolated perfused heart model.35 The ability of this construct to be used in vivo, however, will require further study.

The role of apoptosis in plaque rupture is being increasingly appreciated. Apoptosis of plaque macrophages, in particular, has been associated with plaque destabilization and rupture. Moreover, the uptake of technetium-labeled annexin in plaques with high macrophage content has been documented in both animal models and humans (Figure 3).36,37 Molecular imaging of apoptosis may thus play an important future role in facilitating the development of novel therapies for diseases of both the myocardium and vulnerable atherosclerotic plaque. Techniques to image cellular necrosis are highly complementary and synergistic with those to image apoptosis, and are discussed in more length in the section on ischemia below.

Fibrosis and Scarring

In ischemic heart disease and heart failure, 2 distinct forms of fibrosis are of interest: the fibrosis that characterizes the healed myocardial infarct and the fibrosis that may occur in the remote myocardium not subject to previous ischemic injury. Delayed-enhancement cardiac magnetic resonance has proven highly valuable in detecting both acute and chronic forms of myocardial injury. However, the gadolinium chelates commonly used in delayed-enhancement cardiac magnetic resonance studies are not targeted agents, with the time-dependent enhancement depending on both myocardial blood flow and volume of distribution.38 Thus when delayed-enhancement cardiac magnetic resonance provides for the direct visualization of necrotic and scarred tissue, conventional contrast agents are unable to distinguish between the 2. Recently, however, a collagen-targeted MRI contrast agent was developed for the molecular imaging of fibrosis that was subsequently used to characterize postinfarction myocardial scarring in a murine model. Figure 4 shows a short-axis CMR image acquired before and after the injection of the collagen-targeted contrast agent (EP-3533), and a corresponding tissue slice in which collagen was stained with Picrosirius red.

Vascular Remodeling

Vascular remodeling is a key pathological attribute in atherosclerosis, aneurysm formation, postangioplasty restenosis, and graft arteriosclerosis. Vascular remodeling involves...
Angiogenesis

Angiogenesis is a complex process, which involves (1) degradation of the basal membrane surrounding the parent vasculature, (2) migration of ECs or progenitor cells, (3) proliferation of quiescent ECs to form new vessels, and (4) alignment and organization of ECs to form tubes.52,53 The process of angiogenesis involves the interplay of many cells including monocyes/macrophages, mast cells, lymphocytes, connective tissue cells, pericytes, ECs and pluripotent progenitor cells, all of which influence the process by secreting soluble angiogenic and antiangiogenic molecules including extracellular matrix and proteolytic enzymes. Targeted imaging of biological markers will be critical for understanding the angiogenic process and tracking novel molecular or genetic therapies. Potential targets for imaging of angiogenesis fall into 3 principal categories; (1) EC markers of angiogenesis; (2) non-ECs involved with angiogenesis; and (3) markers of the extracellular matrix.

Perhaps the most widely used strategy for molecular imaging of either adaptive or pathological angiogenesis has been to target endothelial integrins that participate in vascular angiogenesis or remodeling. For the most part, probes have been targeted to specific matrix-binding integrin heterodimers that signal EC migration, proliferation and survival such as αv-integrins (αvβ3, αvβ5) and α5-integrins.54,55 Specificity for angiogenic vessels is somewhat decreased when diffusible rather than pure intravascular imaging probes are used because inflammatory cells and fibroblasts can express many of these integrins. Nonetheless, imaging of αvβ3 with targeted radionuclide and PET probes have been shown to detect angiogenesis in recent myocardial infarction in animals and in humans (Figure 5).56,57 These tracers tend to localize in regions where perfusion is most profoundly reduced.56 In models of chronic limb ischemia without necrosis, targeted αvβ3 radiotracer-based imaging58 or targeted contrast ultrasound of only endothelial αv-integrin expression has been shown to detect both endogenous and growth-factor stimulated arteriogenesis, and to predict future flow recovery.59 Because neovascularization in atherosclerotic lesions is also characterized by α5-integrin expression, the strategy of targeting αvβ3 with MRI probes has been used to detect atherosclerotic disease in animal models.60

Targeted imaging of growth factor receptors has also been used to detect vascular remodeling. Growth factor imaging has most frequently relied on either using radionuclide-labeled vascular endothelial growth factor (VEGF) isoforms as a targeting moiety, or antibodies against specific VEGF signaling receptors such as flt-1 (KDR).61,62

The immune response plays a critical role in angiogenesis and arteriogenesis, in part by providing a source for proangiogenic growth factors (VEGFs, fibroblast growth factors, platelet-derived growth factor), cytokines (interleukin-1, tumor necrosis factor-α, CCL2, CD40L), and proteases required for vascular sprouting and/or remodeling. Gene-targeted deletion of adhesion molecules or cytokine receptors that mediate the inflammatory response results in impaired arteriogenesis in ischemic tissues.63,64 Targeting contrast ultrasound imaging of monocyte recruitment and EC adhesion molecule (vascular cell adhesion molecule-1 [VCAM-1]) expression has recently been shown to herald vascular remodeling in limb ischemia before any significant flow recovery (Figure 5).65 This strategy also has been used to detect immune response dysfunction associated with impaired arteriogenesis.65 In a related matter, immune cell activity is probably reflected by the signal from diffusible imaging probes targeted to matrix proteases that participate in tissue and vascular remodeling. These probes have been shown to enhance in recent MI and in proliferative atherosclerotic lesions and reflect key regulatory processes in neovessel formation or development of collaterals.66,67
Targeting Specific Cardiovascular Diseases

Atherosclerosis

Atherosclerosis is characterized by the thickening of the arterial wall to form an atherosclerotic plaque, a process in which cholesterol deposition, inflammation, extracellular-matrix formation and thrombosis have important roles. Symptoms occur late in the course of disease and are usually caused by the narrowing of the lumen of the artery, which can happen gradually (as a result of progressive plaque growth) or suddenly (as a result of plaque rupture and, subsequently, thrombosis). The resultant decrease in blood supply can affect almost any organ, although coronary heart disease and stroke are the most common consequences.

Traditionally, diagnosis of atherosclerosis was possible only at advanced stages of disease, either by directly revealing the narrowing of the arterial lumen (stenosis) or by evaluating the effect of arterial stenosis on organ perfusion. However, new imaging approaches allow the assessment not only of the morphology of blood vessels but also of the composition of the vessel walls, enabling atherosclerosis-associated abnormalities in the arteries (including the coronary arteries) to be observed, down to the cellular and molecular level.

Because inflammation has a crucial role at all stages of atherosclerosis, macrophages are currently one of the most appealing targets. Ultrasound long-circulating superparamagnetic iron-oxide nanoparticles are engulfed by macrophages in vivo, and this causes a detectable decrease in the MRI signal in proportion to the degree of atherosclerotic plaque inflammation, as shown in human studies. These nanoparticles can also be derivatized with optical and nuclear reporters to facilitate validation with fluorescence techniques and use of PET to enhance sensitivity. A strong correlation between macrophage density and MRI signal was also found recently in a mouse model of atherosclerosis, by using a contrast agent consisting of Gd3+ loaded micelles targeted to the macrophage scavenger receptor. This same technique has also been used to image oxidized low-density lipoprotein in atheromatous plaques with MRI (Figure 6). Using biomimicry and lipoproteins, such as high-density lipoprotein, a multimodal molecular imaging probe for macrophages has been demonstrated to be very flexible. Similarly, in rabbits, specific uptake of an iodine-containing contrast agent by macrophages allows inflamed atherosclerotic lesions to be detected with CT (Figure 6). The signal from [18F]fluorodeoxyglucose correlates with the concentration of macrophages in human atherosclerotic plaques. The concurrent use of several imaging techniques—for example, PET together with CT or, recently, MRI—enables sensitive and reproducible detection of vascular inflammation. This hybrid approach allows the most appropriate technique for a particular patient, vascular region, and disease stage to be chosen and takes advantage of the particular strengths of each modality.

The early detection of disease is one of the principal aims of molecular imaging. Cell-adhesion molecules participate in the early development of atherosclerotic lesions by facilitating the recruitment of leukocytes into the vessel wall. Increased amounts of vascular cell-adhesion molecule 1 (VCAM-1) were found in aortic plaques of apoE−/− mice by using a dual contrast agent detectable by both MRI and fluorescence imaging (Figure 6). Another possibility is to use probes that emit a detectable signal only after they have been activated by the target. For example, in a recent study in rabbits, a fluorescent probe activated by enzymatic degrada-

---

**Figure 5.** Angiogenesis imaging. A, Imaging of integrin expression in a patient 2 weeks after acute anterior myocardial infarction. Magnetic resonance images with delayed gadolinium enhancement (left panel) and hybrid PET/CT perfusion imaging with 13N-ammonia (middle) demonstrate a large infarction in the anteropapical segments. PET performed after injection of an 18F-labeled probe targeting integrin by an RGD sequence detected tracer uptake in the infarct region (right), reproduced with permission. B, Ultrasound molecular imaging of inflammation in angiogenesis in mouse ischemic hindlimb. Data are shown for microbubbles targeted to monocytes and VCAM-1 (C). Corresponding examples of molecular imaging with targeted microbubbles at day 2 and immunohistostchemistry for monocyte α-integrin (red) and VCAM-1 are shown to the right of each graph. *P<0.05 versus control microbubble signal, reproduced with permission.66
tion was used to reveal intraplaque protease activity with a near-infrared fluorescence intravascular catheter. In addition, nuclear reporters, capable of detecting the presence of proteases, have been synthesized (Figure 6). Targeted probes can also be used for therapeutic purposes to deliver drugs in a targeted manner. The potential of this strategy was demonstrated in a study in which rabbits were administered paramagnetic nanoparticles loaded with an antiangiogenic drug. The subsequent reduction in the extent of new blood vessel formation in the atherosclerotic plaques could be monitored noninvasively with MRI by imaging the extent of nanoparticle uptake.

Ischemic Injury
Myocardial damage during ischemic injury is mediated by the following 3 distinct processes: (1) the ischemic episode itself, (2) reperfusion following the ischemic episode, and (3) the inflammatory response to the ischemic event. CM death during ischemic injury can be mediated through either apoptosis or necrosis. Apoptotic cell death dominates during the first 4 to 6 hours of injury, after which necrosis becomes the dominant form of cell death. Molecular imaging of CM apoptosis is discussed extensively above. A necrosis specific imaging agent (based on an antimyosin antibody) has been developed for both nuclear and MR application. An antibody to P-selectin has also been conjugated to micron-sized iron oxide nanoparticles, and VCAM-1 expression has been imaged with a targeted magnofluorescent nanoparticle. Several platforms, thus, exist to image the endothelial expression of adhesion molecules in active and recently ischemic myocardium.

Neutrophil migration into ischemic myocardium begins within a few hours of the ischemic event and peaks within the first 24 hours of injury. This is followed by biphasic monocyte recruitment, with an inflammatory monocyte subset dominating on the first 2 to 3 days and a second subset that promotes angiogenesis dominant on days 4 to 7. A molecular contrast agent, targeted to the leukotriene B4 receptor, and capable of selectively imaging neutrophil infiltration of the myocardium, has previously been described. In addition, the imaging of monocyte/macrophage infiltration into ischemic myocardium can be robustly imaged with both MRI and fluorescence tomography. Long circulating iron oxide nanoparticles are avidly taken up by macrophages infiltrating the myocardium, which can then be imaged in vivo with both T2*-weighted (negative contrast), and off resonance (positive contrast) MRI (Figure 7). A highly linear relationship was seen between the dose of nanoparticles injected and the amount of contrast generated in the myocardium. Labeling the nanoparticles with a near infrared fluorochrome also allowed the infiltrating monocytes/macrophages to be imaged in vivo with fluorescence tomography.

Postinfarction Remodeling
During the first 2 weeks after MI, innate immunity mounts an inflammatory response in the infarcted tissue that evolves into a complex wound healing process. Poor healing can result in infarct expansion and adverse remodeling of remote areas of the myocardium, resulting in chamber dilation and hypertrophy, and a downward spiral leading to overt heart failure. Targeted imaging of components of the inflammatory and healing processes can predict remodeling in animal
models. During the early inflammatory phase, the extent and quality of neutrophil and monocyte subset influx regulates subsequent stages of infarct healing. These innate immune cells have been imaged in murine models with activatable gadolinium-serotonin chelates and nanoparticles that can be detected optically or with MRI. Furthermore, key enzymes that are released by monocyte/macrophages can be targeted with optical, MRI, and nuclear reporters. Specifically, MMPs and cathepsins degrade the preexisting, necrotic extracellular matrix within the infarct area and can be imaged quantitatively with activatable “smart” agents. The presence of MMP in the infarct has been quantified by nuclear imaging in several animal models by targeting the active site of this enzyme with small molecules tagged with SPECT isotopes. Both, the presence of macrophages and the activity of released proteases have been related to prognosis in animal models, which may open a diagnostic and consequently a therapeutic window to augment healing processes. In later stages of wound healing, integrins have been imaged to follow angiogenesis, which is crucial for the supply of evolving granulation tissue. Moreover, the transglutaminase Factor XIII has been shown to play an important role in organizing the new matrix in the scar with clinically relevant sequelae. FXIII has been imaged with an 111In-labeled peptide substrate that becomes crosslinked to surrounding matrix proteins in the evolving scar (Figure 7). These studies have shown that imaging tools that follow inflammation and healing after MI can successfully identify individuals at risk of heart failure, and may in future be used to personalize therapy.

Heart Failure
It is well established that local activation of the renin-angiotensin system contributes to heart failure, and thus a number of targeted agents have been developed to probe the function of the renin-angiotensin system by molecular imaging methods. One approach involves radiolabeling ACE inhibitors for detection by SPECT or PET, whereas another focuses on the angiotensin II type 1 receptor (AT1) by radiolabeling AT1 receptor antagonists. Recent data suggest that heart failure can be characterized in terms of an innate immune response to diverse forms of tissue injury. Because NF-κB plays a central role in proinflammatory responses, a noninvasive assessment of NF-κB expression might offer new insight into the role of inflammatory activation during heart failure. Toward this end, a transgenic mouse expressing luciferase under the control of the NF-κB promoter was used to noninvasively characterize NF-κB expression over time after myocardial infarction using bioluminescence imaging (BLI). In the setting of ischemic heart failure, viable myocardium often exhibits a shift in substrate utilization from aerobic (free-fatty acids) to anaerobic (glucose) metabolism. PET and SPECT probes for assessing myocardial metabolism were summarized in Part I of this Series, including 2-(18F) fluoro-2-deoxy-D-glucose (FDG) for assessing glucose uptake by PET and 123I-methyl-P-iodophenylpentadecanoic

Figure 7. Ischemia and post-MI remodeling. A–E, Magnetofluorescent imaging of postinfarction myocardial monocyte/macrophage infiltration. A, T2*-weighted MRI, 96 hours after infarction, shows the accumulation of iron oxide nanoparticles in the infarct (signal hypointensity) due to their uptake by infiltrating macrophages, reproduced with permission. B, Off-resonance image in the same animal model as in A producing positive contrast from the iron oxide nanoparticles, reproduced with permission. C, FMT imaging after injection of magnetofluorescent nanoparticles shows high fluorescent signal in the region of the heart (M.N. and Ralph Weissleder, unpublished data). D, Ex vivo fluorescence reflectance imaging confirms in vivo FMT. E, Fluorescent microscopy of the myocardial infarct in the 680-nm channel shows the microscopic distribution of the nanoparticles, reproduced with permission. F–L, Serial MRI and SPECT-CT imaging of infarct healing and left ventricular remodeling. SPECT imaging of FXIII activity in the healing infarct predicts the degree of LV remodeling. F and I, Delayed enhancement MR images on day 2 post-MI show similar infarct size and LV volumes in mice without (F–H) and with (I–L) FXIII therapy. FXIII activity on day 3 is significantly higher in the treated mouse (G, K) and correlates with less adverse remodeling by day 21 post-MI (H, L), adapted with permission. 

Downloaded from circimaging.ahajournals.org at Massachusetts General Hospital on January 21, 2009
acid for assessing free fatty acid uptake by SPECT. Heart failure is also characterized by dysfunctional baroreceptor reflex control and elevated levels of plasma norepinephrine. Elevated plasma norepinephrine is a strong predictor of mortality in patients with advanced heart failure,\textsuperscript{101} and is associated with the downregulation and uncoupling of $\beta$-adrenergic receptors in cardiac myocytes. Part I of this series reviewed a radiolabeled $\beta$-blocker for PET imaging ($^{11}C$-CGP12177) with potential utility in assessing $\beta$-adrenergic receptor function in the setting of heart failure.\textsuperscript{1}

Part I also reviewed approaches for measuring presynaptic function by PET using $^{11}C$-meta-hydroxyephedrine or by SPECT using $^{123}I$-meta-iodobenzylguanidine.\textsuperscript{1} Apoptosis and an imbalance of the myocardial flow/function and angiogenesis/hypertrophy relationship plays a major role in the pathogenesis of heart failure. Thus, targeted imaging of apoptosis and angiogenesis (described earlier) might also prove diagnostic in certain forms of heart failure.

**Transplant Rejection**

The current clinical standard for graft surveillance consists of serial endomyocardial biopsies. However, this procedure suffers from a substantial sampling error and complications. These limitations and the discomfort of the invasive procedure motivated assessment of molecular imaging techniques to report on organ rejection. One of the first attempts to image heart transplant rejection used an $^{111}$In-labeled antibody targeted to myosin, the intracellular contractile protein that is shielded behind the cell membrane in intact myocytes.\textsuperscript{102} $^{99m}$Tc-labeled annexin-V has been used to image rejection in patients after heart transplantation.\textsuperscript{32} Ho and colleagues harnessed the high propensity of dextran-coated iron oxide nanoparticles for uptake by phagocytes to image rejection by MRI. They used long circulating macrophage-avid iron oxide nanoparticles in rats with transplant rejection, and found a 30% signal change 24 hours after injection\textsuperscript{103} and a good correlation between signal change in MRI and pathological rejection grade. The same group used micron-sized iron oxide particles to image macrophage uptake in rejected cardiac grafts in rats,\textsuperscript{104} with a more punctuate change in MR signal. BLI has been used to monitor graft survival in rodents.\textsuperscript{105}

Although this work introduces an elegant research tool to monitor graft survival noninvasively, clinical translation of BLI is not feasible. Using an ultrasound-based approach, Weller et al\textsuperscript{106} designed microbubbles that target the adhesion molecule ICAM-1, which allowed detection of graft rejection of heterotopic heart transplants in rats.

**Monitoring Cell-Based Therapies**

Iron oxide nanoparticles yield negative contrast on T2*-weighted images even with small intracellular amounts and appear to have a wide safety profile with little effect on cellular function.\textsuperscript{107,108} Transfection agents or electroporation are used to encourage cellular uptake in nonphagocytic cells.\textsuperscript{109,110} Using delayed contrast enhanced MRI for guidance during interventional MRI, targeting of the injections to the peri-infarcted region of the myocardium can be performed.\textsuperscript{111,112} Because the majority of the adult stem cells does not survive and engraft, there remains an intense debate as to whether hypointensities imaged at later time points represent intact, live engrafted cells, residual free iron, or iron within macrophages.\textsuperscript{113,114} Direct labeling of cells with fluorinated compounds\textsuperscript{115} has also been used and suffers from similar limitations as iron oxide labeling. Rapid cell proliferation and division may dilute the label in the daughter cell—leading to the inability to detect labeled cells after 6 to 8 cell divisions.\textsuperscript{116} Even without cell division, the reliable detection limit of a cluster of iron oxide-labeled cells in the beating heart at clinical field strengths is on the order of 100 000 cells.\textsuperscript{117} Therefore, detection of iron oxide-labeled stem cells after intravenous injection is difficult due to the small number of cells that home to injured myocardium.\textsuperscript{118} The strength of direct cell labeling with iron oxide nanoparticles is the ability to determine the initial delivery of the cellular therapeutic to the heart without exposing the stem cells or the patient to ionizing radiation. A novel method to enhance stem cell viability and enable cell tracking has been the addition of MRI-labeled cells to tissue matrices\textsuperscript{119} or the addition of contrast agents to microencapsulation materials.\textsuperscript{120} In the latter case, the imaging label can be added at a higher concentration to the porous barrier than would be possible for intracellular labeling without compromising cell viability. Indeed, radiopaque contrast agents have now been used to create x-ray–visible stem cells. This new technique may provide the ideal marriage of stem cell labeling with current cardiovascular interventional techniques that are primarily x-ray based (Figure 8).

Reporter gene imaging of stem cells overcomes some of the limitations of direct cell labeling. Here, the stem cells are genetically modified to express reporter genes before transplantation. The reporter gene DNA construct can be transferred into cells via a viral (eg, lentivirus, retrovirus, adeno- virus, adeno-associated virus) or nonviral vector (eg, plasmid). Translation of the reporter gene mRNA produces a protein, that when exposed to the complementary probe, generates an imaging signal.\textsuperscript{121} Commonly used promoters are constitutive (continuous expression), inducible (controlled expression), or cell/tissue specific. Varying the promoter sequence can provide information about stem cell differentiation and mechanism of therapy. For example, including a cardiac specific promoter (eg, $\alpha$-cardiac myosin heavy-chain promoter) that will express a reporter gene when the cells differentiate into cardiac phenotype will allow selection of cardiac differentiated cells among undifferentiated stem cells.

Frequently used reporter gene imaging constructs include firefly luciferase ($Fluc$)-based optical bioluminescence (BLI),\textsuperscript{122,123} sodium-iodide symporter ($NIS$) for SPECT imaging,\textsuperscript{124} and herpes simplex virus thymidine kinase (HSV-tk)-based PET imaging.\textsuperscript{125,126} For BLI, the reporter gene is $Fluc$, which oxidizes the substrate D-Luciferin to produce light, similar to how light is generated within the firefly insect (Figure 8). However, this technique is restricted to small animal use because the emitted photons become attenuated within deep tissues and thus are currently not applicable to large animal or human studies. By contrast, the $HSV$-tk reporter gene constructs have been applied to large animals\textsuperscript{126--128} and in human studies involving adoptive cell
The basis behind this approach is injecting the subject with a radiolabeled thymidine analogue (e.g., \([18F]\)fluoro-3-hydroxymethylbutylguanine or \([18F]\)-FHBG) that can be detected by PET when it is phosphorylated by HSV-tk and subsequently trapped inside the cell. A drawback to Fluc, NIS, and HSV-tk is that the stem cells must be genetically modified before transplantation. However, the advantage is that only viable cells will produce a signal. Likewise, proliferation of stem cells stably expressing the reporter gene can be detected by progressive rise of imaging signals over time. Finally, if the transplanted cells are apoptotic or dead, the reporter genes will be absent, thus minimizing false signals.

Because each imaging modality possesses unique limitations and advantages, multimodality imaging constructs have been developed that combine the best features of each technology in an attempt to satisfy all the needs of stem cell imaging. One example is the triple fusion reporter gene construct that consists of monomeric red fluorescence protein (mRFP), Fluc, and HSV-tk. Each portion of the multimodality imaging construct provides its unique benefits: mRFP allows isolation of the stably transduced cell population and Fluc enables high throughput in small animal models. In addition, HSV-tk enables PET imaging in small animals, large animals, and patients.

**Monitoring Gene Therapy**

Gene therapy aims at the vector-mediated overexpression of endogenous or exogenous genes for molecular intervention with the disease process. It has been tested in various cardiovascular diseases, including ischemia, heart failure and arrhythmias. Many basic tools and principles remain under development, and questions concerning delivery methods, therapeutic efficacy and safety remain open. Molecular imaging provides valuable tools to address these open issues noninvasively.

To track the therapeutic agent directly, the advent of cardiac gene therapy has promoted the development of...
reporter gene imaging techniques for the heart. Following gene transfer, detection of the level of reporter gene product activity is achieved through accumulation of a reporter probe which provides indirect information on the level of reporter gene expression, but also reflects endogenous signaling and transcription factors which drive reporter gene expression. The gene product of suitable reporter genes is usually not present in target tissue and has little effects or interaction with tissue function. It can be an enzyme that catalyzes specific accumulation of an imaging reporter probe (eg, HSV-tk accumulating radiolabeled nucleosides, luciferase metabolizing luciferin for light production), a receptor which accumulates specific receptor ligand probe (eg, dopamine D2 receptor accumulating radiolabeled ligands), or a transport protein which results in intracellular accumulation of specific probe molecules (eg, NIS accumulating radioiodine, iron nanoparticles, or technetium). This technique has been initially introduced using autoradiography, and has since been translated from small rodents to large experimental animals, where it allows for noninvasive assessment of location, magnitude and persistence of transgene expression. Coexpression of a reporter gene will allow for indirect imaging of the expression of a therapeutic gene of choice, and linkage of measures of transgene expression to downstream functional effects will enhance the understanding of basic mechanisms of cardiac gene therapy (Figure 8). More recently, it has also been suggested that reporter gene imaging can be used for imaging of more specific myocardial conditional gene activation.

**Integrative and Multimodal Approaches**

A successful molecular imaging strategy requires the use of a sensitive and specific agent to the target of choice, the ability to image the anatomic distribution of the agent with a high degree of certainty and spatial resolution, and the ability to integrate the molecular and anatomic images with a functional or physiological readout in that organ. The breadth and flexibility of molecular MRI allows these requirements to be met in many scenarios. However, molecular MRI has significantly lower sensitivity than SPECT, PET and fluorescence techniques. SPECT, PET and fluorescence on the other hand do not provide adequate anatomic information and have significantly lower resolution. A compelling case can thus be made for a multimodal imaging approach that exploits the strengths of several modalities.

At the preclinical level, high resolution small animal PET-CT and SPECT-CT systems are becoming increasingly standard. However, cardiovascular structures in mice are often of submillimeter in diameter, which profoundly challenges the spatial resolution of nuclear and fluorescence imaging. Prototypes of integrated FMT-CT and FMT-MR systems are therefore under development. Integration of CT and MRI with PET and FMT datasets has been performed offline by including fiducial markers in the field of view, and by using advanced shape/pattern recognition software that supports off-line fusion at submillimeter precision. Unlike PET-CT systems, where the images are acquired sequentially, MR-PET systems have been designed to perform the acquisition of the MR and PET signals simultaneously. Whole body MR-PET systems for human imaging are currently under development and will likely play an important role in cardiovascular imaging.

The concept of hybrid imaging can be extended even further by performing multimodal molecular imaging with several platforms. This could allow a cluster of biomarkers to be imaged together in a systems approach. The combination of fluorescence, MRI and PET or SPECT imaging, for instance, could allow >4 targets to be imaged at one time. Potential applications of this strategy include inflammatory atherosclerosis where imaging of the adhesion molecule VCAM-1 could be performed with a PET reporter, the recruitment of monocyte/macrophages could be imaged with magneto-fluorescent nanoparticles, and the assessment of their proteolytic activity could be detected with near infrared protease sensors. This comprehensive molecular imaging strategy would offer a global view of events, rather than focusing in isolation on a single molecule.

**Potential Clinical Impact**

Molecular imaging has the potential to impact cardiovascular medicine in several ways, including the assessment of risk, the early detection of disease, the development of personalized and targeted therapeutic regimens, and the monitoring of therapeutic efficacy and outcome. In addition to these direct implications, molecular imaging will affect clinical care indirectly by facilitating the more rapid development of novel pharmaceuticals and improving the basic understanding of cardiovascular pathophysiology.

The clinical role of cardiovascular molecular imaging is still emerging, although several completed studies involving clinical patients have already demonstrated the feasibility and potential value of molecular imaging. The established clinical value of metabolic imaging and neuroreceptor imaging was previously outlined in Part I of this consensus. Other examples of targeted clinical imaging include the uptake of 99mTc-labeled annexin-V, iron oxide nanoparticles or 18F-deoxyglucose in carotid plaques in humans, which has been associated with macrophage rich plaques and clinical instability. These agents could thus conceivably be used to detect plaque vulnerability in appropriately selected patient populations. The fibrin sensing gadolinium chelate EP2104R has now been given to patients with a clinical suspicion of thrombosis, and could play a valuable role in the diagnosis and monitoring of deep venous thrombosis, pulmonary embolism, left atrial appendage thrombosis and embolic stroke. The uptake of 99mTc-annexin-V has also been shown to predict an adverse clinical course in patients with heart failure, and also potential rejection in patients with heart transplantation.

As the cost and complexity of clinical care continue to escalate, an algorithmic approach to patient therapy based on outcome results from large clinical trials will need to be complemented by a personalized approach involving biomarkers and molecular imaging. The initial clinical experience with gene or stem cell therapy for treatment of ischemic heart disease, for instance, has been inconsistent and difficult to interpret in the absence of molecular imaging specifically targeted at the biological end point (ie, angiogenesis or myocardial...
repair). The simple evaluation of clinical outcomes or physiological consequences may be too insensitive to detect a potential true biological effect. Therefore, complex new therapies of this sort will require molecular imaging for a more sensitive and robust assessment of their therapeutic efficacy.

Barriers to Translation

The attributes and limitations of each of the imaging modalities reviewed in Part I of this consensus document present a unique set of translational challenges specific to each modality. SPECT and PET imaging offer high sensitivity, relatively low cost, and a minimal potential for adverse bioeffects, providing the quickest route for translation of molecular imaging to patients. However, this advantage needs to be balanced by the additive exposure to ionizing radiation associated with serial nuclear imaging. The importance of this radiation exposure in cardiovascular imaging is being increasingly realized and is of particular relevance to molecular imaging, which could involve serial imaging of otherwise young healthy people. In addition, the limited resolution of nuclear imaging requires anatomic colocalization of nuclear images with higher resolution anatomic x-ray CT images particularly if absolute quantification of the targeted radiotracers is required. Although the use of hybrid SPECT-CT and PET-CT imaging systems will clearly improve the accuracy of nuclear-based molecular imaging approaches, the benefit of this additional quantitative accuracy will come at the cost of exposure to 2 sources of ionizing radiation. Although many clinical scenarios will arise where the risks of radiation exposure will be far out weighted by the information obtained from the hybrid nuclear-CT molecular images, this will need to be carefully assessed on a case-by-case basis.

The lower sensitivity of MR-based molecular imaging approaches creates the principal barrier to their clinical translation. Highly expressed targets, such as fibrin and type 1 collagen, can be imaged with small gadolinium chelates that have pharmacokinetics very similar to those of clinically used gadolinium chelates. However, many other targets in the cardiovascular system are focal or of low volume and require agents with much higher sensitivity. Gadolinium containing nanoparticles provide the required increase in sensitivity but their pharmacokinetics and elimination are complex. The potential for tissue retention of gadolinium and subsequent systemic fibrosis will need to be rigorously addressed with all gadolinium-based probes, but will be of particular importance in the case of activatable and nanoparticulate gadolinium-containing constructs.

The clinical experience with iron-oxide nanoparticles for liver and lymph node imaging is fairly extensive and has revealed an excellent safety profile. However, the safety of these agents for serial imaging studies will need to be more rigorously addressed. Clear dosing guidelines will need to be developed to avoid any risk of iron overload. The risk of an immune reaction to the material coating the nanoparticle associated with repeat injections will also need to be carefully assessed. The advantages of MR-based molecular imaging, which does not involve exposure to ionizing radiation, will need to be weighed carefully against the more complex pharmacokinetics of these agents.

Fluorescence molecular tomography (FMT) is an extremely valuable technique for molecular imaging of small animal that cannot be easily translated to humans with current detector technology. However, noninvasive fluorescence imaging of large superficial vessels such as the carotid and femoral arteries might be possible. In contrast, fluorescence imaging of the coronary arteries will undoubtedly require the use of intravascular optical catheters, a prototype of which has recently been developed. Organic NIR cyanine fluorochromes, such as indocyanine green, have been used clinically for many years and are highly analogous to experimental NIR fluorochromes that are currently entering phase 1 clinical trials. The use of quantum dots for fluorescence imaging in clinical practice, however, remains unlikely due to the highly toxic moieties contained within these agents.

The routine application of molecular imaging in the management of patients with cardiovascular disease is likely close. Molecular imaging should develop further with appropriate education of the cardiovascular community and the increased availability of various hybrid imaging systems (SPECT-CT, PET-CT, PET-MRI) that will facilitate quantification of molecular imaging agents. A number of challenges, however, stand in the way of realizing these promises. Current imaging systems have not been optimized for cardiac applications, with inadequate correction for cardiac and respiratory motion and a lack of quantitative software for targeted agents. Full realization of the promise of cardiovascular molecular imaging will thus require an ongoing and concerted collaboration between industry, and the basic science and imaging communities.

Conclusion

As the field of molecular imaging gains momentum, we will see a continuously increasing number of imaging biomarkers in preclinical and clinical studies. Preclinical research will continue to be accelerated by noninvasive, sensitive, and longitudinal assessment of therapeutic targets. “Smart” amplification strategies, comparative head-to-head analysis of markers, improved reporter performance, and improving hardware will enable us to detect minuscule or trace amounts of novel targets. These noninvasive targeted approaches will have to be tested for their prognostic value, cost effectiveness, and potential long term toxicity to translate these technological advances into improved patient care.

Sources of Funding

This work was supported in part by American Heart Association Scientist Development Grant 0835623D (to M.N.); National Institutes of Health grants R01 HL093038 and K08 HL079984 (to D.E.S.); grant R01 HL085093 and a Department of Veterans Affairs Merit Award (to M.M.S.); grant R21/R33 HL089027 (to J.C.W.); grants R21/R33 HL089029, 2008-MSCR-0399-00 (Maryland Stem Cell Research Fund), and R01 EB007825 (to D.L.K.); and grants R01 HL078650 and R01 HL065662 (to A.J.S.).

Disclosures

None.

Downloaded from circimaging.ahajournals.org at Massachusetts General Hospital on January 21, 2009


40. Helm PA, Caravan P, French BA, Jacques V, Shen L, Xu Y, Bever JY, Roy RJ, Kramer CM, Epstein FH. Postinfarction myocardial scarring in


